Screening Protocol for the Evaluation of Research Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01036217|
Recruitment Status : Completed
First Posted : December 21, 2009
Last Update Posted : July 2, 2017
- The National Institute on Drug Abuse (NIDA) uses a standardized set of procedures to develop a pool of potential participants for research studies. Because some of the data collected during screening are used later for research, the screening itself is considered a study. An applicant to any NIDA study is considered a participant in NIDA screening.
- To identify, recruit, and screen participants for NIDA research protocols.
- Individuals 18 years of age and older who are able to provide informed consent.
- Individuals who are eligible for screening will undergo two interviews: a telephone interview and an in-person interview. The phone interview will determine eligibility for the in-person interview.
- The in-person interview may require up to five visits to NIDA. The in-person visit will involve any or all of the following procedures: (1) full physical examination and medical history; (2) psychiatric interview; (3) psychological testing; (4) electrocardiogram; (5) samples of blood, urine, and hair; and (6) other minimally invasive procedures as directed by the research staff.
- During screening, a photograph will be taken for confirmation of identity during subsequent visits for other studies.
- No clinical care will be provided as part of screening.
|Condition or disease|
|Substance Abuse Disorders|
|Study Type :||Observational|
|Estimated Enrollment :||55000 participants|
|Official Title:||Evaluation of Potential Research Subjects - Screening Protocol for Clinical Studies|
|Study Start Date :||May 17, 2006|
|Study Completion Date :||June 17, 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01036217
|United States, Maryland|
|National Institute on Drug Abuse, Biomedical Research Center (BRC)|
|Baltimore, Maryland, United States, 21224|